Format

Send to

Choose Destination
Oncotarget. 2018 Apr 13;9(28):20119-20133. doi: 10.18632/oncotarget.24614. eCollection 2018 Apr 13.

Mouse models of multiple myeloma: technologic platforms and perspectives.

Author information

1
Department of Experimental and Clinical Medicine, "Magna Graecia" University of Catanzaro, Catanzaro, Italy.
2
Department of Health Sciences, Magna Graecia University, Catanzaro, Italy.
3
Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, USA.

Abstract

Murine models of human multiple myeloma (MM) are key tools for the study of disease biology as well as for investigation and selection of novel candidate therapeutics for clinical translation. In the last years, a variety of pre-clinical models have been generated to recapitulate a wide spectrum of biological features of MM. These systems range from spontaneous or transgenic models of murine MM, to subcutaneous or orthothopic xenografts of human MM cell lines in immune compromised animals, to platform allowing the engraftment of primary/bone marrow-dependent MM cells within a human bone marrow milieu to fully recapitulate human disease. Selecting the right model for specific pre-clinical research is essential for the successful completion of investigation. We here review recent and most known pre-clinical murine, transgenic and humanized models of MM, focusing on major advantages and/or weaknesses in the light of different research aims.

KEYWORDS:

SCID; SCID-hu; SCID-synth-hu; mouse models; multiple myeloma

Conflict of interest statement

CONFLICTS OF INTEREST The authors declare no conflicts of interest.

Publication type

Publication type

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center